Dubai, Oct. 2013

Close to 90 delegates converged from all over Middle East and North Africa, to the first ever ASPIRE (Annual Summit on Progress In Relapsing MS in the Middle East) in Dubai.

Top neurologists from the region joined some of the most prominent MS experts in the world to exchange scientific insights and share the latest developments in research and clinical practice in the field of MS

The full day meeting included presentations and discussions around clinical studies. It also gave the attendees the opportunity to discuss the place of Aubagio (Teriflunomide) in daily practice and in the treatment algorithm that was recently published by a group of MS experts from the Middle East and North Africa.

Aubagio is the latest oral therapy to be approved by the FDA and the EMA for the treatment of patients suffering from relapsing forms of Multiple Sclerosis (MS). Karim Smaira, CEO of Genpharm expressed his gratitude to the large turnaround and the level of interaction during the meeting. “I have participated in many CME meetings during my career and this is definitely one of the best programs I have been involved in. Teriflunomide is an excellent alternative for patients diagnosed with relapsing forms of Multiple Sclerosis. Its once daily oral regimen and the results demonstrated through robust and long terms clinical trials are exciting for the whole community of patients and physicians alike. This was clearly reflected in the discussions throughout the day”.

Several delegates emphasized their satisfaction with the event. “This was the best meeting and advisory board I attended over the last five years… The speakers were a good selection of top class experts and topics were very relevant… I couldn’t think of anything more to improve these events. It’s difficult to change excellence”, said Prof. Deleu.

“The program was very well organized added to it the presence of distinguished speakers and the contents of their talks was really to the point and updated… there was enough time for discussion and interaction… In general I found this meeting was fruitful and was worth to be attended”, said Dr. Sarmad Alshamaa

Click on the photo to watch the meeting highlights